e treatment of prostate cancers that do metastasize has been revolutionized by the understanding that prostate cancer is an androgen-driven disease. Androgens exert their e ects through binding to the androgen receptor, which is normally found in the cytoplasm and is maintained in an inactive state through the association of a number of other proteins, including the heat-shock proteins Hsp90, Hsp70, and Hsp40. Androgen binding triggers the androgen receptor's release and it moves into the nucleus and acts as a transcription factor, binding to genes that contain androgen response elements and stimulating their expression. Many of the target genes are involved in the growth, survival, and proliferation of prostate cancer cells ( Figure 1 ).
FIGURE 1
The androgen receptor is predominantly found in an inactive state in the cytoplasm in a complex with other proteins, including heatshock proteins (eg, Hsp90, Hsp70, and Hsp40). It is activated upon binding of testosterone or its more active metabolite 5-DHT. Ligand binding releases the androgen receptor from its complex and facilitates N/C dimerization and exposure of a nuclear localization signal that allows the receptor to move into the nucleus. Inside the nucleus it acts as a transcription factor, binding to target genes through androgen response elements. Feature thesis of testosterone in the testes or that block the body's ability to use androgens. 4 Although the majority of patients respond initially, the cancer almost invariably becomes castration-resistant prostate cancer (CRPC). Researchers initially believed that CRPC developed the ability to grow independently of androgens, but evidence accumulated that the AR pathway was still very much activated in these cancers. Instead, it seems that tumor cells nd alternative ways to active AR signaling, for example, through mutations or ampli cation of the AR gene or through mutations in the ligand-binding domain that allow the AR to be activated by lower levels of testosterone or by other ligands. 5, 6 With this knowledge, researchers began to focus their e orts on targeting the AR pathway in more e ective ways in CRPC, prompting numerous approvals of drugs with varying mechanisms of action. e more potent and selective AR antagonist enzalutamide was approved in 2012 on the basis of the phase 3 AFFIRM trial in which it demonstrated improved overall survival (OS) compared with placebo. 6 An alternative way of targeting the AR pathway is through the use of inhibitors of the CYP17A enzyme that plays an important role in androgen synthesis. Abiraterone acetate was approved in 2011 and also signi cantly improved OS over placebo. 7 e approval of the rst therapeutic vaccine, sipuleucel-T, in 2010 for the treatment of CRPC validated the use of immunotherapy as an e ective treatment strategy in prostate cancer. 8 Despite the expanding treatment options, improvements in OS were modest and patients still ultimately develop resistance, thus there remains a pressing need for new drugs. Ongoing clinical trials are evaluating nextgeneration AR-targeting drugs that are ever more potent and speci c and that target other parts of the AR, such as the N-terminal domain rather than the ligand-binding domain. e most clinically advanced of these drugs is the novel anti-androgen ARN-509, for which the phase 3 SPARTAN trial is underway and is expected to complete enrollment sometime this year. ODM-201, a synthetic androgen receptor, is being examined in the phase 3 ATLAS trial, which also began enrolling patients recently. Both of those drugs bind to the AR with higher a nity than enzalutamide.
More speci c CYP17A inhibitors are also being tested, and orteronel was looking particularly promising until disappointing phase 3 results prompted discontinuation of its development program. 10 Drugs with a combined mechanism of action, both AR antagonist and CYP17A inhibitor, could also prove more e ective. e phase 3 ARMOR-SV trial of galeterone, the rst in this novel drug class, is underway and expected to complete enrollment in the next 6 months.
Renal cell carcinoma: a hat-trick of recent approvals Kidney cancer, most often presenting as renal cell carcinoma (RCC), accounts for about 4% of all adult malignancies. 11 RCC is actually a heterogeneous aggregate of several di erent subtypes of disease that di er in their histology and clinical course. It can be subdivided into two major groups: clear cell and non-clear cell. Non-clear cell RCC (nccRCC) can be further divided into several other subtypes, including papillary, chromophobe, collecting duct, and renal medullary RCC. 12 In general, patient outcomes for all types of kidney cancer are poor since it often goes undiagnosed until the advanced stages and is notoriously resistant to chemotherapy. But thanks to genome sequencing studies that FIGURE 2 The majority of renal cell carcinomas display dysregulation of the VHL pathway. The von Hippel Lindau (VHL) protein is part of an E3 ubiquitin ligase complex, which tags target proteins with ubiquitin molecules that act as a signal to the proteasomal machinery that those proteins need to be destroyed and removed from the cell. Among VHL's targets is the hypoxiainducible factor 1-alpha (HIF1-alpha), an oxygen-sensing transcription factor that mediates the expression of numerous genes in the nucleus, including those involved in angiogenesis, growth and survival, cell proliferation and other cancer hallmarks. Reproduced with permission: Tojo A. Paraneoplastic glomerulopathy associated with renal cell carcinoma. In Chen J, ed. Renal tumor. Rijeka, Croatia: InTech; 2013. http://www.intechopen.com/books/renaltumor/paraneoplastic-glomerulopathy-associated-with-renal-cell-carcinoma. Accessed have vastly improved our understanding of the molecular mechanisms underlying di erent types of kidney cancer, the situation is steadily beginning to improve, particularly for ccRCC for which there has been a slew of recent drug approvals.
e majority of these tumors exhibit dysregulation of the VHL protein, a component of an E3 ubiquitin ligase complex that plays a central role in "tagging" proteins for destruction by the proteasome. Among its targets is hypoxia-inducible factor 1-alpha (HIF1-alpha), a transcription factor that regulates the cellular response to hypoxia by mediating the expression of a number of di erent genes, including the vascular endothelial growth factor (VEGF) (Figure 2) .
Another frequently altered signaling pathway in ccRCC is the mammalian target of rapamycin (mTOR) pathway, which promotes many of the hallmarks of malignant transformation. mTOR dysregulation is also linked to the VHL pathway, as activation of mTOR has been shown to increase HIF1-alpha levels and thus stimulate VEGF expression. 13, 14 Drugs designed to target mTOR and VEGF have proved highly e ective in the treatment of RCC, realizing substantial gains in progression-free survival (PFS), but only one improves OS and none o ers long-term, durable remission. e development of acquired resistance to these targeted therapies is a pressing issue in the design of novel drugs. 15 Research e orts culminated in three approvals in the past year. Several signaling pathways have been implicated in the development of resistance to VEGF-targeted therapy, among them the hepatocyte growth factor receptor (MET) and broblast growth factor receptors (FGFRs) pathways. 16 Multi-targeted kinase inhibitors have been developed that target both the VEGF receptors and other kinases.
Cabozantinib, for example, includes the MET receptor among its other targets. When compared with the mTOR inhibitor everolimus in the phase 3 METEOR trial, it consistently improved PFS across all subgroups examined, in addition to improving OS. 17 On the basis of that trial, it was approved by the FDA for the treatment of patients with metastatic RCC who have received previous antiangiogenic therapy.
Targeting the MET receptor may also prove to be a promising therapeutic strategy for a type of nccRCC. Papillary RCC is commonly subdivided into type 1 and type 2 tumors on the basis of histological di erences, but genome sequencing studies have suggested the divide is also a molecular one. e majority of type 1 cases are associated with MET alterations, suggesting they may be susceptible to MET inhibition. Clinical trials testing this hypothesis are ongoing and the results of a phase 2 study of foretinib were recently published, demonstrating an objective response rate of 13.5% among 74 patients and median PFS of 9.3 months. 18, 19 Meanwhile, lenvatinib targets the platelet-derived growth factor receptor (PDGFR), RET, c-KIT and FGFR 1-4 in addition to the VEGFRs. It was approved in combination with everolimus on the basis of a phase 2 trial in which patients with advanced/metastatic RCC whose disease progressed following VEGF-targeted therapy experienced a signi cant improvement in PFS when treated with the combination compared with either agent alone. 20 e third approval was for a very di erent therapeutic strategy, one that has received signi cant attention in recent years and revolutionized the treatment of several di erent cancer types. e immune checkpoint inhibitor nivolumab, which acts to knock out the tumor's ability to hide itself from the immune system, was awarded regulatory approval on the basis of the phase 3 CheckMate-025 trial in which it signi cantly improved OS compared with everolimus. 21 ese approvals have greatly expanded the second-line treatment options for patients whose disease progresses on VEGF-targeted therapy.
Bladder cancer: immunotherapy yields key approval Unlike prostate and kidney cancers, outcomes for patients with bladder cancer have remained stubbornly poor, with 5-year survival rates of just 15% among patients with advanced disease. 22 Since the approval of cisplatin-based combination chemotherapy more than two decades ago, there had been no other FDA-approved treatment options for patients with metastatic disease. e paucity of e ective therapeutic options was not for lack of trying as many di erent treatment strategies have been tested, including small-molecule inhibitors and monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2), both overexpressed in a signicant proportion of bladder cancers, broblast growth factor receptor (FGFR) inhibitors, since FGFR mutations are commonly seen in this tumor type, and anti-angiogenic drugs, given that the central regulator of angiogenesis, the vascular endothelial growth factor (VEGF) and its receptor are often overexpressed also. Some clinical trials are ongoing (Table 1) but for the most part, have proven disappointing. 23, 24 More recently, the persistence has paid o and a focus on immunotherapy has nally yielded another approved treatment. Cancer cells present a range of unusual proteins on their surface that should serve as antigens, recognizable by the patient's immune system. However, cancer cells are able to suppress this immune response by manipulating the expression of proteins that regulate it, such as the target of atezolizumab, programmed cell death ligand-1 (PD-L1).
e approval for atezolizumab was based on data from Feature Further results from a cohort of 119 patients with cisplatin-ineligible disease who were receiving atezolizumab as rst-line therapy in the IMvigor210 study were presented at the 2016 annual meeting of the American Society of Clinical Oncology. Among these patients almost a quarter responded to atezolizumab treatment, with median OS of 14.8 months. e fact that this drug was well tolerated in both settings is particularly noteworthy, because bladder cancer tends to occur in older patients who are less able to tolerate the toxicity of chemotherapy.
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Testicular cancer: progress limited by heterogeneity Testicular cancer is rare, accounting for just 1% of all malignancies, but its incidence has been increasing in many Western countries in the past several decades and it is the most common solid tumor among men aged 15-35 years.
anks to its unprecedented sensitivity to chemotherapy in combination with surgical resection, the cure rate for testicular cancer exceeds 90%. 27 Nonetheless, a proportion of patients develop resistance to chemotherapy and experience relapse or progression despite treatment and the cure rate among these patients is signi cantly lower, mostly as a result of limited treatment options. e molecular mechanisms of resistance to chemotherapy are still poorly understood and the targeted therapies that have been examined as potential treatment options have had limited success. In general, the common mutations in oncogenes and tumor suppressors that are observed in other tumor types are relatively rare in testicular cancers and among the potentially targetable genomic alterations that have been identi ed, such as mutations in the FGFR, AKT and PIK3CA genes, it is unclear what role these might play in the development of chemoresistance, if any. 28 Some progress is being made in certain types of testicular cancer and several di erent treatment strategies continue to be evaluated. Among those drugs that look promising in early-stage clinical testing are cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors. ese enzymes play a critical role in the regulation of the cell cycle and have emerged as promising drug targets for several di erent types of cancer. Mature teratomas, tumors that most commonly occur in the testes, have been shown to express high levels of the retinoblastoma protein (pRb). Since pRb expression is tightly regulated by CDK4/6 it was hypothesized that CDK inhibitors might be e ective in the treatment of these tumors.
e results of a phase 2 study of the CDK4/6 inhibitor palbociclib in patients with pRb-expressing germ cell tumors were recently published. Among 29 patients who were evaluable for response, the 24-week PFS rate was 28% and toxicity was manageable. Bene t was observed mainly in patients with unresectable teratomas and teratomas with malignant transformation. 29 Cancer stem cells, a group of cells possessing stem celllike properties within the tumor, have been identi ed in most tumor types and mounting evidence suggests that these cells are hypermalignant and extremely resistant to various current cancer treatments and may be responsible for the metastatic potential of tumors. 30 As such, they represent an interesting new drug target. e lead candidate BBI-608 targeting the stemness phenotype of these cells is also being evaluated in early-stage clinical trials in testicular cancer.
